-Reuters
Morgan Stanley Maintains Equal-Weight on Gilead Sciences, Raises Price Target to $81
Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:GILD) with a Equal-Weight and raises the price target from $68 to $81.
Related Posts
Kohl’s Shareholder Macellum Advisors Issues Statement Related To Co.’s Annual Meeting, Says Is Committed To Holding Co. Board Accountable Until Meaningful Shareholder Value Is Unlocked
Macellum Advisors GP, LLC (together with its affiliates, “Macellum” or “we”), a long-term holder of nearly 5% of the outstanding common shares of Kohl’s Corporation (NYSE:KSS)
Piper Sandler Upgrades Washington Trust Bancorp to Overweight, Announces $58 Price Target
Piper Sandler analyst Mark Fitzgibbon upgrades Washington Trust Bancorp (NASDAQ:WASH) from Neutral to Overweight and announces $58 price target.
RBC Capital Maintains Sector Perform on Ritchie Bros Auctioneers, Raises Price Target to $72
RBC Capital analyst Sabahat Khan maintains Ritchie Bros Auctioneers (NYSE:RBA) with a Sector Perform and raises the price target from $65 to $72.